New England Journal of Medicine , 389, 514-526
These effects form the foundation of incretin-based obesity therapy and have been studied extensively since semaglutides approval in 2017
Wegovy 2.4 mg FlexTouch solution for injection Summary of Product Characteristics
shows robust anti-obesity, anti-diabetic, and cardiometabolic effects in preclinical and clinical studies, including significant reductions in body weight, glycemic markers, blood pressure, and lipids 1,3,5
(19) Liraglutide was found to improve bone mineral density and mitigate the detrimental effects of glucocorticoids on bone metabolism
Therefore, CD38 expression increases with age and HFD-induced obesity in major organs such as the liver, skeletal muscle, and lungs, decreasing NAD + levels [58,59,60,61,62,63]